Moleculin

MBRX NASDAQ
1.060
-0.020
-1.85%
盘后: 1.150 +0.09 +8.49% 18:46 08/16 EDT
开盘
1.090
昨收
1.080
最高
1.100
最低
1.060
成交量
9.89万
成交均量(3M)
36.10万
52周最高
3.150
52周最低
0.7772
换手率
0.22%
市值
4,790.36万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Moleculin MBRX股票价格,Moleculin股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
展开 >

最近浏览

名称
价格
涨跌幅